GlassScriptPhysician profile
Don B Bandari
NPI 1558362673
$96,155.86
in general payments reported to CMS, 2019-2025
31 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $11K · 2021: $15K · 2022: $15K · 2023: $15K · 2024: $15K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $43K · Food and Beverage: $1,462 · Education: $28.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $43,200.00 |
| Food and Beverage | $1,462.32 |
| Education | $28.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $92,250.87 | 2019-2025 | Venacure 1470 Pro, Venacure 1470 Pro |
| E.R. Squibb & Sons, L.L.C. | $826.07 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $481.19 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $458.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $429.24 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $208.16 | 2019-2023 | Farxiga |
| Amgen INC. | $176.43 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $176.41 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $119.51 | 2022-2024 | Opsumit |
| Pfizer INC. | $105.92 | 2019-2025 | |
| Medtronic, INC. | $103.42 | 2022 | |
| Amarin Pharma, INC. | $93.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $81.79 | 2019-2022 | |
| Astellas Pharma US INC | $73.73 | 2020-2023 | Myrbetriq |
| Lilly USA, LLC | $71.96 | 2019-2023 | Mounjaro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.56 | 2019-2020 | |
| Bardy Diagnostics, INC. | $56.34 | 2021-2022 | |
| Abiomed | $54.75 | 2025 | |
| Arbor Pharmaceuticals, INC. | $49.96 | 2019 | |
| Boston Scientific Corporation | $47.78 | 2023-2025 | Varithena Administration Pack, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $42.51 | 2019-2023 | |
| Medtronic Vascular, INC. | $29.48 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.05 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $20.84 | 2019 | |
| Abbott Laboratories | $18.82 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.65 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.29 | 2023 | Inpefa |
| Amryt Pharma Holdings LTD | $17.17 | 2021 | |
| Abbvie INC. | $16.58 | 2023 | Viberzi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.23 | 2021 | |
| Allergan, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Bandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.